BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/11/2025 8:20:58 AM | Browse: 85 | Download: 332
 |
Received |
|
2025-09-05 13:52 |
|
Peer-Review Started |
|
2025-09-05 13:53 |
|
First Decision by Editorial Office Director |
|
2025-09-16 07:58 |
|
Return for Revision |
|
2025-09-16 07:58 |
|
Revised |
|
2025-09-28 14:40 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-11-03 02:43 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-03 09:45 |
|
Articles in Press |
|
2025-11-03 09:45 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-12-02 01:44 |
|
Publish the Manuscript Online |
|
2025-12-11 08:20 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Lymphocyte to C-reactive protein ratio as a novel inflammatory biomarker: Validation and clinical relevance as an independent prognostic factor in cholangiocarcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Fan Xiao, De-Hua Zhou, Guo-Wei Liu, Chao-Wei Lin, Zi-You Wu, Hua Yu, Wei Gong and Wei-Feng Tan |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82170412 |
|
| Corresponding Author |
Wei-Feng Tan, MD, PhD, Professor, Hepatobiliary Surgery Center, Tongji Hospital, School of Medicine, Tongji University, No. 389 Xincheng Road, Putuo District, Shanghai 200092, China. twf1231@163.com |
| Key Words |
Cholangiocarcinoma; Lymphocyte to C-reactive protein ratio; Overall survival; Surgical site infection; Hospital stay; Prognostic biomarker; Radical resection; Inflammatory response |
| Core Tip |
This pioneering study establishes the lymphocyte to C-reactive protein ratio (LCR) as the first validated inflammatory biomarker for predicting survival and postoperative outcomes in cholangiocarcinoma. We demonstrate that a low preoperative LCR (< 180) independently correlates with a 4.5-fold increase in the risk of prolonged hospitalization, elevated risk of surgical site infections (odds ratio = 4.41), and significantly reduced median survival (14.93 months vs 46.67 months). As a cost-effective prognostic tool, LCR facilitates refined patient stratification, thereby supporting optimized surgical decision-making and postoperative management. |
| Publish Date |
2025-12-11 08:20 |
| Citation |
Xiao F, Zhou DH, Liu GW, Lin CW, Wu ZY, Yu H, Gong W, Tan WF. Lymphocyte to C-reactive protein ratio as a novel inflammatory biomarker: Validation and clinical relevance as an independent prognostic factor in cholangiocarcinoma. World J Gastrointest Oncol 2025; 17(12): 113853 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i12/113853.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i12.113853 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
